A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6

Linda Baughn, Maurizio Di Liberto, Kaida Wu, Peter L. Toogood, Tracey Louie, Rachel Gottschalk, Ruben Niesvizky, Hearn Cho, Scott Ely, Malcolm A.S. Moore, Selina Chen-Kiang

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Cell cycle deregulation is central to the initiation and fatality of multiple myeloma, the second most common hematopoietic cancer, although impaired apoptosis plays a critical role in the accumulation of myeloma cells in the bone marrow. The mechanism for intermittent, unrestrained proliferation of myeloma cells is unknown, but mutually exclusive activation of cyclin-dependent kinase 4 (Cdk4)-cyclin D1 or Cdk6-cyclin D2 precedes proliferation of bone marrow myeloma cells in vivo. Here, we show that by specific inhibition of Cdk4/6, the orally active small-molecule PD 0332991 potently induces G 1 arrest in primary bone marrow myeloma cells ex vivo and prevents tumor growth in disseminated human myeloma xenografts. PD 0332991 inhibits Cdk4/6 proportional to the cycling status of the cells independent of cellular transformation and acts in concert with the physiologic Cdk4/6 inhibitor p18INK4c. Inhibition of cdk4/6 by PD 0332991 is not accompanied by induction of apoptosis. However, when used in combination with a second agent, such as dexamethasone, PD 0332991 markedly enhances the killing of myeloma cells by dexamethasone. PD 0332991, therefore, represents the first promising and specific inhibitor for therapeutic targeting of Cdk4/6 in multiple myeloma and possibly other B-cell cancers.

Original languageEnglish (US)
Pages (from-to)7661-7667
Number of pages7
JournalCancer Research
Volume66
Issue number15
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

Fingerprint

Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 4
Bone Marrow Cells
Growth
Neoplasms
Multiple Myeloma
Dexamethasone
Cyclin D2
Apoptosis
Cyclin D1
Heterografts
Cell Cycle
B-Lymphocytes
Cell Proliferation
palbociclib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. / Baughn, Linda; Di Liberto, Maurizio; Wu, Kaida; Toogood, Peter L.; Louie, Tracey; Gottschalk, Rachel; Niesvizky, Ruben; Cho, Hearn; Ely, Scott; Moore, Malcolm A.S.; Chen-Kiang, Selina.

In: Cancer Research, Vol. 66, No. 15, 01.08.2006, p. 7661-7667.

Research output: Contribution to journalArticle

Baughn, L, Di Liberto, M, Wu, K, Toogood, PL, Louie, T, Gottschalk, R, Niesvizky, R, Cho, H, Ely, S, Moore, MAS & Chen-Kiang, S 2006, 'A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6', Cancer Research, vol. 66, no. 15, pp. 7661-7667. https://doi.org/10.1158/0008-5472.CAN-06-1098
Baughn, Linda ; Di Liberto, Maurizio ; Wu, Kaida ; Toogood, Peter L. ; Louie, Tracey ; Gottschalk, Rachel ; Niesvizky, Ruben ; Cho, Hearn ; Ely, Scott ; Moore, Malcolm A.S. ; Chen-Kiang, Selina. / A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. In: Cancer Research. 2006 ; Vol. 66, No. 15. pp. 7661-7667.
@article{8bd48ea31b124cfa9e120b446656bdc7,
title = "A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6",
abstract = "Cell cycle deregulation is central to the initiation and fatality of multiple myeloma, the second most common hematopoietic cancer, although impaired apoptosis plays a critical role in the accumulation of myeloma cells in the bone marrow. The mechanism for intermittent, unrestrained proliferation of myeloma cells is unknown, but mutually exclusive activation of cyclin-dependent kinase 4 (Cdk4)-cyclin D1 or Cdk6-cyclin D2 precedes proliferation of bone marrow myeloma cells in vivo. Here, we show that by specific inhibition of Cdk4/6, the orally active small-molecule PD 0332991 potently induces G 1 arrest in primary bone marrow myeloma cells ex vivo and prevents tumor growth in disseminated human myeloma xenografts. PD 0332991 inhibits Cdk4/6 proportional to the cycling status of the cells independent of cellular transformation and acts in concert with the physiologic Cdk4/6 inhibitor p18INK4c. Inhibition of cdk4/6 by PD 0332991 is not accompanied by induction of apoptosis. However, when used in combination with a second agent, such as dexamethasone, PD 0332991 markedly enhances the killing of myeloma cells by dexamethasone. PD 0332991, therefore, represents the first promising and specific inhibitor for therapeutic targeting of Cdk4/6 in multiple myeloma and possibly other B-cell cancers.",
author = "Linda Baughn and {Di Liberto}, Maurizio and Kaida Wu and Toogood, {Peter L.} and Tracey Louie and Rachel Gottschalk and Ruben Niesvizky and Hearn Cho and Scott Ely and Moore, {Malcolm A.S.} and Selina Chen-Kiang",
year = "2006",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-06-1098",
language = "English (US)",
volume = "66",
pages = "7661--7667",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6

AU - Baughn, Linda

AU - Di Liberto, Maurizio

AU - Wu, Kaida

AU - Toogood, Peter L.

AU - Louie, Tracey

AU - Gottschalk, Rachel

AU - Niesvizky, Ruben

AU - Cho, Hearn

AU - Ely, Scott

AU - Moore, Malcolm A.S.

AU - Chen-Kiang, Selina

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Cell cycle deregulation is central to the initiation and fatality of multiple myeloma, the second most common hematopoietic cancer, although impaired apoptosis plays a critical role in the accumulation of myeloma cells in the bone marrow. The mechanism for intermittent, unrestrained proliferation of myeloma cells is unknown, but mutually exclusive activation of cyclin-dependent kinase 4 (Cdk4)-cyclin D1 or Cdk6-cyclin D2 precedes proliferation of bone marrow myeloma cells in vivo. Here, we show that by specific inhibition of Cdk4/6, the orally active small-molecule PD 0332991 potently induces G 1 arrest in primary bone marrow myeloma cells ex vivo and prevents tumor growth in disseminated human myeloma xenografts. PD 0332991 inhibits Cdk4/6 proportional to the cycling status of the cells independent of cellular transformation and acts in concert with the physiologic Cdk4/6 inhibitor p18INK4c. Inhibition of cdk4/6 by PD 0332991 is not accompanied by induction of apoptosis. However, when used in combination with a second agent, such as dexamethasone, PD 0332991 markedly enhances the killing of myeloma cells by dexamethasone. PD 0332991, therefore, represents the first promising and specific inhibitor for therapeutic targeting of Cdk4/6 in multiple myeloma and possibly other B-cell cancers.

AB - Cell cycle deregulation is central to the initiation and fatality of multiple myeloma, the second most common hematopoietic cancer, although impaired apoptosis plays a critical role in the accumulation of myeloma cells in the bone marrow. The mechanism for intermittent, unrestrained proliferation of myeloma cells is unknown, but mutually exclusive activation of cyclin-dependent kinase 4 (Cdk4)-cyclin D1 or Cdk6-cyclin D2 precedes proliferation of bone marrow myeloma cells in vivo. Here, we show that by specific inhibition of Cdk4/6, the orally active small-molecule PD 0332991 potently induces G 1 arrest in primary bone marrow myeloma cells ex vivo and prevents tumor growth in disseminated human myeloma xenografts. PD 0332991 inhibits Cdk4/6 proportional to the cycling status of the cells independent of cellular transformation and acts in concert with the physiologic Cdk4/6 inhibitor p18INK4c. Inhibition of cdk4/6 by PD 0332991 is not accompanied by induction of apoptosis. However, when used in combination with a second agent, such as dexamethasone, PD 0332991 markedly enhances the killing of myeloma cells by dexamethasone. PD 0332991, therefore, represents the first promising and specific inhibitor for therapeutic targeting of Cdk4/6 in multiple myeloma and possibly other B-cell cancers.

UR - http://www.scopus.com/inward/record.url?scp=33747872306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747872306&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-06-1098

DO - 10.1158/0008-5472.CAN-06-1098

M3 - Article

C2 - 16885367

AN - SCOPUS:33747872306

VL - 66

SP - 7661

EP - 7667

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 15

ER -